Literature DB >> 18928223

Surgical treatment for delayed pyogenic spondylitis after percutaneous vertebroplasty and kyphoplasty. Report of 4 cases.

Jae-Hyuk Shin1, Kee-Yong Ha, Ki-Won Kim, Jun-Seok Lee, Min-Wook Joo.   

Abstract

Only 6 cases of pyogenic spondylitis following vertebroplasty or kyphoplasty have been reported, and their causes remained unclear. The authors report on 4 cases of delayed pyogenic spondylitis (DPS) following vertebroplasty or kyphoplasty for osteoporotic compression fractures and metastatic disease. Four patients presented with DPS after vertebroplasty or kyphoplasty and underwent surgical treatment. Clinical history, laboratory examination, and MR imaging confirmed the diagnosis of DPS. Anterior debridement, reconstruction, and posterior instrumented fusion were performed. The mean interval for the delayed occurrence of pyogenic spondylitis after surgery was 12.3 months. The infections were primarily bacterial in origin, but most patients also suffered diverse medical comorbidities. Despite successful treatment of the infections, comorbidity was and is a factor that compromises good results. Medical comorbidities associated with compromised immunity may increase susceptibility to DPS after vertebroplasty or kyphoplasty. In cases of incapacitating back pain after a pain-free period following either of these surgeries, evaluation of the erythrocyte sedimentation rate and C-reactive protein level and examination of contrast-enhanced MR imaging studies are essential to rule out delayed vertebral infection. Surgical treatment requires cement removal and anterior reconstruction with or without additional posterior instrumented fusion.

Entities:  

Mesh:

Year:  2008        PMID: 18928223     DOI: 10.3171/SPI/2008/9/9/265

Source DB:  PubMed          Journal:  J Neurosurg Spine        ISSN: 1547-5646


  9 in total

1.  Causes of late revision surgery after bone cement augmentation in osteoporotic vertebral compression fractures.

Authors:  Kee-Yong Ha; Young-Hoon Kim; Dong-Gunn Chang; Il-Nam Son; Ki-Won Kim; Sung-Eun Kim
Journal:  Asian Spine J       Date:  2013-11-28

2.  Minimally invasive percutaneous endoscopic treatment for acute pyogenic spondylodiscitis following vertebroplasty.

Authors:  Myung Soo Youn; Jong Ki Shin; Tae Sik Goh; Jung Sub Lee
Journal:  Eur Spine J       Date:  2018-01-22       Impact factor: 3.134

3.  Late onset tuberculous spondylitis following kyphoplasty: a case report and review of the literature.

Authors:  Hee Jin Kim; Dong Ah Shin; Kyung Gi Cho; Sang Sup Chung
Journal:  Korean J Spine       Date:  2012-03-31

4.  Transforaminal Endoscopic Lumbar Discectomy: Basic Concepts and Technical Keys to Clinical Success.

Authors:  Sang Gu Lee; Yong Ahn
Journal:  Int J Spine Surg       Date:  2021-12

Review 5.  Vertebroplasty in the management of painful bony metastases.

Authors:  Michael Gofeld; Anuj Bhatia; Allen W Burton
Journal:  Curr Pain Headache Rep       Date:  2009-08

6.  Tuberculous Spondylitis Following Kyphoplasty: A Case Report and Review of the Literature.

Authors:  Chao-Yuan Ge; Li-Ming He; Yong-Hong Zheng; Tuan-Jiang Liu; Hua Guo; Bao-Rong He; Li-Xiong Qian; Yuan-Tin Zhao; Jun-Song Yang; Ding-Jun Hao
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

7.  Surgical outcomes of infectious spondylitis after vertebroplasty, and comparisons between pyogenic and tuberculosis.

Authors:  Jen-Chung Liao; Po-Liang Lai; Lih-Hui Chen; Chi-Chien Niu
Journal:  BMC Infect Dis       Date:  2018-11-12       Impact factor: 3.090

8.  Risk factors for tuberculous or nontuberculous spondylitis after percutaneous vertebroplasty or kyphoplasty in patients with osteoporotic vertebral compression fracture: A case-control study.

Authors:  Bo-Wen Zheng; Fu-Sheng Liu; Bo-Yv Zheng; Hua-Qing Niu; Jing Li; Guo-Hua Lv; Ming-Xiang Zou; Zhun Xu
Journal:  Front Surg       Date:  2022-08-18

9.  Tuberculous spondylitis after percutaneous vertebroplasty: A case series of 9 cases.

Authors:  Po-Ju Lai; Jen-Chung Liao; Lih-Hui Chen; Po-Liang Lai
Journal:  Biomed J       Date:  2019-09-12       Impact factor: 4.910

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.